2023-506697-12-00CompletedPhase 1
MK-8507 Extended Multiple Dose Study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 May 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 17 Aug 2023
- Start date
- 20 Oct 2023
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- HIV
- EU CT number
- 2023-506697-12-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 80
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Advanced Technology Corporation | Liege | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.